|Bid||81.47 x 800|
|Ask||140.00 x 800|
|Day's Range||85.80 - 88.80|
|52 Week Range||83.96 - 130.00|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||122.00|
There are few, if any, more innovative, more daring, and more iconic health care executives. We'll hear about the process that drives groundbreaking invention, and her dream of permanently alleviating the shortage of transplantable organs.Martine Rothblatt, founder and CEO of United Therapeutics presents her organization's latest innovation, followed by a conversation with "Fast Money" Host and "Power Lunch" co-anchor, Melissa Lee.
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching United Therapeutics Corporation (NASDAQ:UTHR) might want to consider the historica...
United Therapeutics Corp NASDAQ/NGS:UTHRView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for UTHR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $5.64 billion over the last one-month into ETFs that hold UTHR are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., May 7, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and DEKA Research & Development Corp. today announced receipt of 510(k) clearance by the U.S. Food and Drug Administration (FDA) for the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also referred to as the RemUnity™ system. The RemUnity system, which has been jointly developed by United Therapeutics and DEKA, is indicated for subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension, or PAH.
United Therapeutics Corp. suffered its first major blow from generic competition as sales of its pulmonary arterial hypertension drug, Adcirca, plummeted in the first quarter of this, driving the company to eye new business lines to make up for the hit. The Silver Spring biotech's first-quarter total revenue was dragged down about 7%, to $362.6 million from $389.2 million in the same period last year. United Therapeutics (NASDAQ: UTHR) sold fewer bottles of the Adcirca tablets after its patent expired and a generic version of the drug hit the market in August, according to Securities and Exchange Commission filings.
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
United Therapeutics (UTHR) delivered earnings and revenue surprises of 35.61% and 9.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Silver Spring, Maryland-based company said it had a loss of $11.32. Earnings, adjusted for non-recurring costs and stock option expense, were $3.58 per share. The results exceeded ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , May 1, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2019. ...
SILVER SPRING, Md., April 29, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that its collaborator, XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (XVIVO.ST), has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the products XPS™ and STEEN Solution™. This approval means that STEEN Solution, XPS and the accompanying single-use articles are the only medical device products that are approved in the United States for ex-vivo lung perfusion (EVLP) of initially unacceptable donated lungs at body temperature.
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2019 financial ...
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 17, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) was named as a defendant, along with Smiths Medical ASD, Inc., in a lawsuit filed in federal court by Sandoz Inc. and RareGen, LLC on April 16, 2019. The lawsuit alleges that United Therapeutics engaged in anticompetitive conduct in connection with plaintiffs' efforts to launch their generic version of Remodulin® (treprostinil) Injection. United Therapeutics was founded with the goal of serving patients with pulmonary arterial hypertension (PAH), and that remains our focus today.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as United Therapeutics Corporation (NASDAQ:UTHR), with a market capitalization of US$4.8b, rarely draw their attention from the investing commun...
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 8, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event. Accordingly, United Therapeutics has decided to discontinue further esuberaprost development.